Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up.
| Published in | Science Journal of Clinical Medicine (Volume 3, Issue 6) |
| DOI | 10.11648/j.sjcm.20140306.14 |
| Page(s) | 117-123 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2014. Published by Science Publishing Group |
ALT, HBV DNA Level, HBeAg Status, Liver Histology
| [1] | World Health Organization: WHO: Hepatitis B. Fact Sheet No. 204. (http://www.who.int/mediacentre/factsheets/fs204/en/) (accessed 4 May 2014). |
| [2] | Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT: National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009; 49(5 Suppl):S4-S12. doi: 10.1002/hep.22946. |
| [3] | Lok AS: Chronic hepatitis B. N Engl J Med. 2002; 346(22):1682-3. |
| [4] | Lee WM: Hepatitis B virus infection. N Engl J Med. 1997; 337(24):1733-45. |
| [5] | Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2):97-107. |
| [6] | Sharma SK, Saini N, Chwla Y: Hepatitis B virus: inactive carriers. Virol J. 2005; 2:82. |
| [7] | Martinelli D, Fortunato F, Simsek G, Prato R: Epidemiology and Prevention of Viral Hepatitis B and C. Practical Management of Chronic Viral Hepatitis. Edited by Serviddio G. Croatia: In Tech; 2013;3-18. |
| [8] | Geller SA, Petrovic LM: Chronic Hepatitis (Chronic Necroinflammatory Disease of the Liver)-Grading and Staging. Biopsy Interpretation of the Liver. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2009;97-120 |
| [9] | Squadrito G, Spinella R, Raimondo G: The clinical significance of occult HBV infection. Ann Gastroenterol. 2014; 27(1):15-19. |
| [10] | Yim HJ, Lok AS: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43(2 Suppl 1):S173-81. |
| [11] | Kim ES, Seo YS, Keum B, Kim JH, A H, Yim HJ, Kim YS, Jeen YT, Lee HS, Chun HJ, Um SH, Duck Kim C, Ryu HS: The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers. Hepat Mon. 2011; 11(5):351-7. |
| [12] | Ijaz B, Ahmad W, Javed FT, Gull S, Hassan S: Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers. Virol J. 2011; 8: 86. |
| [13] | European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85. |
| [14] | Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007; 20 Suppl 1:S3-14. |
| [15] | Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG: Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013; 11(3):303-8.e1. |
| [16] | Christensen C, Bruden D, Livingston S, Deubner H, Homan C, Smith K, Oh E, Gretch D, Williams J, McMahon B: Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat. 2006; 13(10):652-8. |
| [17] | Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H: Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol. 2014; 86(1):131-8. |
| [18] | Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008; 6(12):1315-41. |
| [19] | Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137(1):1-10. |
| [20] | Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology. 2007; 45:507-39. |
| [21] | Keshvari M, Alavian SM, Sharafi H: How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level? Hepat Mon. 2014; 5:e15285. |
| [22] | McMahon BJ: Chronic hepatitis B virus infection. Med Clin North Am 2014, 98:39-54. |
| [23] | Tong MJ, Trieu J: Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis. 2013; 14(6):311-7 |
| [24] | Gastroenterological Society of Australia and Digestive Health Foundation: Australian and New Zealand chronic hepatitis B (CHB) recommendations. Clinical update [webpage on the Internet] Victoria, Australia: The Digestive Health Foundation; 2008. Available from: http://www.gesa.org.au/files/editor_upload/File/Professional/CHB.pdf. Accessed May 5, 2014. http://www.nzsg.org.nz/uploads/Documents/HepBClinical.pdf |
| [25] | Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: comparison of current treatment guidelines. World J Gastroenterol. 2012; 18(42):6106-13. |
| [26] | Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1):65-73. |
| [27] | Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, Dong JQ: Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol. 2007; 13(14):2104-7. |
| [28] | Alam S, Ahamd N, Alam K, Mostafa G, Khan M: Correlation between Hepatitis B Viral DNA Load and Extent of Liver Pathology in Patients with Chronic Hepatitis B. Hepatitis Monthly. 2008, 8(3):185-9 |
| [29] | Madan K, Batra Y, Jha JK, Kumar S, Kalra N, Paul SB, Singh R, Duttagupta S, Panda SK, Acharya SK: Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.Trop Gastroenterol. 2008; 29(2):84-90. |
| [30] | Peng J, Luo K, Zhu Y, Guo Y, Zhang L, Hou J: Clinical and histological characteristics of chronic hepatitis B with negative hepatitis B e-antigen. Chin Med J (Engl). 2003; 116(9):1312-7. |
| [31] | Xiao L, Xian J, Li Y, Geng A, Yang X, Han L, Xu H: Parameters associated with significant liver histological changes in patients with chronic hepatitis B. ISRN Gastroenterol. 2014;2014:913890. doi: 10.1155/2014/913890. eCollection 2014. |
| [32] | Mansour-Ghanaei F, Rafiei R, Joukar F, Naghipour M, Besharati S, Aminian K, Atrkar-Roushan Z: Relationship between serum HBV DNA level and liver histology in HBV carriers with normal ALT in Guilan province, Iran. Med Sci Monit. 2010; 16(3):BR97-101. |
| [33] | Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, Papoutselis M, Maltezos E, Sivridis E, Papoutselis K: The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol. 2008; 49(6):884-91. |
| [34] | Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, Marcellin P: Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002; 36(4):543-6. |
| [35] | Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A: Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57(1):196-202. |
| [36] | Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R: Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J. 2007; 83(975):32-9. |
| [37] | Chu CJ, Hussain M, Lok AS: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002; 36(6):1408-15. |
| [38] | Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ: Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. J Clin Microbiol. 2003; 41(10):4793-5. |
| [39] | Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000-summary of a workshop. Gastroenterology. 2001; 120(7):1828-53. |
| [40] | Dancygier H: Hepatitis B. Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Volume 2. Edited by Dancygier H. Berlin Heidelberg: Springer; 2010:743-80 |
APA Style
Ali Koyuncuer. (2014). Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B. Science Journal of Clinical Medicine, 3(6), 117-123. https://doi.org/10.11648/j.sjcm.20140306.14
ACS Style
Ali Koyuncuer. Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B. Sci. J. Clin. Med. 2014, 3(6), 117-123. doi: 10.11648/j.sjcm.20140306.14
AMA Style
Ali Koyuncuer. Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B. Sci J Clin Med. 2014;3(6):117-123. doi: 10.11648/j.sjcm.20140306.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjcm.20140306.14,
author = {Ali Koyuncuer},
title = {Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B},
journal = {Science Journal of Clinical Medicine},
volume = {3},
number = {6},
pages = {117-123},
doi = {10.11648/j.sjcm.20140306.14},
url = {https://doi.org/10.11648/j.sjcm.20140306.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20140306.14},
abstract = {Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up.},
year = {2014}
}
TY - JOUR T1 - Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B AU - Ali Koyuncuer Y1 - 2014/11/10 PY - 2014 N1 - https://doi.org/10.11648/j.sjcm.20140306.14 DO - 10.11648/j.sjcm.20140306.14 T2 - Science Journal of Clinical Medicine JF - Science Journal of Clinical Medicine JO - Science Journal of Clinical Medicine SP - 117 EP - 123 PB - Science Publishing Group SN - 2327-2732 UR - https://doi.org/10.11648/j.sjcm.20140306.14 AB - Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up. VL - 3 IS - 6 ER -
Email: